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4Abstract
Animal studies investigating the efficacy of neurotrophic factors as treatments for Parkinson’s
disease (PD) ideally require partial dopamine (DA) lesion models. The intra-striatal 6-
hydroxydopamine (6-OHDA) lesion model may be suitable for this purpose. Although this
model has been well characterized in rodents, it has not previously been used in monkeys. The
goal of the present study was to characterize the behavioural effects of unilateral injections of
6-OHDA in the basal ganglia of common marmoset monkeys (Callithrix jacchus). Cell counts
from tyrosine hydroxylase immunochemistry five months postlesion revealed DA cell loss in
the substantia nigra on the lesioned side of ~46% relative to the unlesioned side. 6-OHDA
lesioned monkeys showed a variety of behavioural deficits. Apomorphine induced rotation and
simple sensorimotor measures (head position bias and PD disability rating score) were most
affected by the lesion. The largest deficits were seen at one or two weeks postsurgery but had
recovered by week ten. 6-OHDA lesioned monkeys took longer to complete a more complex
sensorimotor staircase task. At 3.5 months postlesion, 6-OHDA monkeys also showed deficits
on an object retrieval task designed to measure sensorimotor planning and skilled hand use. a-
Methyl-p-tyrosine, a tyrosine hydroxylase inhibitor, reinstated those deficits which had
undergone recovery in the lesioned animals and also exacerbated the deficits on the staircase
task. This model has potential in assessing treatments for PD aimed at curtailing disease
progression such as continuous delivery of neurotrophic factors.
Key words: Marmoset; Monkey; Parkinson’s disease; 6-Hydroxydopamine; Dopamine; Basal
ganglia; Substantia nigra; Caudate; Accumbens; Putamen
5Introduction
Parkinson’s disease (PD) is one of the most common debilitating neurodegenerative diseases,
with 1-2 individuals affected for every 1000 (9, 16, 35). The disease manifests itself as
bradykinesia, rigidity and resting tremor (20) with patients frequently presenting cognitive
deficits (6, 42). The neuropathology underlying PD centres primarily on a severe, but subtotal,
loss of dopamine (DA) cells in the substantia nigra pars compacta (SNpc) (12, 25).
A variety of strategies has been developed in the search for an effective treatment for PD.
These strategies can be broadly classified as those attempting to control the symptoms of the
disorder and those attempting to halt or reverse disease progression (17). The mainstay of the
former approach includes the use of dopamine replacement drugs such as L-DOPA (54). More
invasive techniques have also been attempted, including brain stimulation (15) and
intracerebral transplantation of foetal dopaminergic cells (7, 23). Unfortunately, such
treatments fail to halt the progress of the disease and are not without risk of serious side
effects (e.g. L-DOPA induced dyskinesias) (44).
Within the last decade, attention has been directed at methods designed to halt or reverse
disease progression. Such strategies include attempts to rescue damaged neurones with the aid
of neurotrophic factors, such as glial cell line-derived neurotrophic factor (GDNF) (4).
Strategies involving GDNF, in particular, seem promising since GDNF has been shown to be
expressed in the developing and adult striatum (26, 40). Furthermore, it has been shown to
increase survival of DA neurones in vitro and in vivo when given before or after mechanical
axotomy (3, 57) or treatment with neurotoxins targeting DA neurones (19, 31, 32, 59).
6Studies investigating neurotrophic factors such as GDNF pose a particular challenge regarding
the appropriate model needed to test its efficacy. In rodents, the in vivo model most commonly
used in PD research involves the unilateral injection of 6-hydroxydopamine (6-OHDA) directly
into the substantia nigra or the medial forebrain bundle (52). These procedures produce DA
depletions in the terminal striatal areas which are almost complete (37, 41). In order to assess
the neuroprotective efficacy of neurotrophic factors, however, a partial lesion animal model is
required (5). Ideally, such a model should parallel the gradual degeneration of DA neurones
characteristic of PD where a small number of DA neurones remain at the end-stage of the
disease (12, 25). These remaining groups of neurones are the targets for neuroprotective
strategies (33). Unfortunately, it is difficult to produce standardized partial lesions by making
sub-total lesions within the substantia nigra or medial forbrain bundle (5). An alternative
approach has been developed in rats in which 6-OHDA is injected directly into the terminal
areas in the striatum. In the past few years, this intrastriatal 6-OHDA model in rats has been
well characterized and been shown to produce suitable partial DA lesions (2, 29, 34, 43). In
this model there is a gradual degeneration, in which the first stage of rapid cell loss (one to
four weeks post-injection) is followed by protracted cell loss continuing for at least four
months (51). The majority of rat studies showing the neuroprotective and neuroregenerative
capacity of GDNF have used this particular partial lesion model (10, 28, 30, 31, 36, 48-50,
59). For example, Kirik and colleagues (31) have shown that administration of a modified
adeno-associated viral vector (AAV) expressing GDNF to rats prior to intrastriatal injection of
6-OHDA was able to protect dopamine cells against the toxic insult and also to result in
preservation of function.
Before treatments using viral vectors expressing GDNF progress to clinical use their safety
and efficacy in monkeys should be assessed as an intermediate step between rodent studies and
7patient trials for a number of reasons. For example, the putamen and caudate nucleus form a
continuous structure in rodents whereas they are discrete structures in humans and monkeys.
Also, there are immunological and pharmacokinetic differences between primates and rodents.
Although there have been monkey studies in which GDNF has been evaluated, they have made
use of the MPTP model of PD (11, 19, 21, 32, 60). Since the majority of rodent studies rely
on the intrastriatal 6-OHDA model, we thought it was important to investigate the efficacy of
GDNF in monkeys based on the same model. This would allow for direct comparison with the
majority of rodent studies testing GDNF. However, the 6-OHDA partial model has not yet
been characterised in monkeys. The goal of the present study was to characterize the
behavioural effects of 6-OHDA lesions within the dopaminergic terminal striatal area in the
common marmoset monkey.
Methods
Animals and Surgery
All procedures were carried out under a Project Licence in accordance with the U.K. Animals
(Scientific Procedures) Act 1986. Twelve adult common marmosets (Callithrix jacchus), 7
males and 5 females, were used. All were laboratory-bred, weighed 320-470g, and were aged
22-35 months at the start of the experiment. All the monkeys were housed with a cage-mate of
similar age. Six monkeys (4 males, 2 females) were given 6-OHDA injections unilaterally, with
9 injections into the striatum (caudate, accumbens, putamen). Six monkeys (3 males, 3
females) were given saline control injections at the same sites. Attempts were made to ensure
that each pair of cage-mates were given unilateral injections in opposite hemispheres. Thus 3
animals in each group had injections in the left hemisphere and 3 had injections in the right
8hemisphere. The coordinates, derived from the stereotaxic atlas of Stephan et al (53), are
shown in Table 1.
For surgery, monkeys were anaesthetized with alphaxalone-alphadolone (Saffan; Schering-
Plough Ltd, Welwyn Garden City, UK; 1.5ml/kg given intramuscularly). Fifteen minutes later
the monkeys were injected with pargyline (Sigma, St Louis, MO, USA; 50mg/kg,
intraperitoneally), a monoamine oxidase inhibitor which prevents the metabolism of 6-OHDA,
thus prolonging its neurotoxic effects. A supplementary dose of 0.3ml Saffan was given during
surgery if necessary. 6-OHDA Hbr (Sigma, St Louis, MO, USA; 4mg/ml free base weight
dissolved in 0.01% ascorbate/saline) was freshly prepared and stored on ice just before use.
Each injection of 2µl 6-OHDA was made at a rate of 0.5µl/min using a 29g injection needle
which was left in place for a further four minutes after each injection had been made. Control
monkeys underwent the same procedures with saline injections. Following surgery the
monkeys were given an analgesic (Finadyne; Schering-Plough Animal Health, Mildenhall, UK;
0.1mg/kg, subcutaneously) and kept in a warm incubator until well enough to be returned to
their home cage, usually the day following surgery.
Histology
When all behavioural testing was finished, the monkeys were perfused for histological analysis
of the brains. The monkeys were premedicated with 0.05ml ketamine (Vetalar; Shering-
Plough, Welwyn garden City, UK; 100mg/ml, intramuscularly) and deeply anaesthetised with
0.6ml sodium pentobarbitone (200mg/ml, intraperitoneally) prior to being perfused. Monkeys
were perfused transcardially with 500ml 0.1M phosphate-buffered saline pH7.4 (PBS),
followed by 1000ml of 4% paraformaldehyde in PBS. Following perfusion, the brains were
9removed and placed in 4% paraformaldehyde solution for 24 hours, after which they were
transferred to 30% sucrose solution in PBS for 4 days at 4oC.
Sections were cut at 60µm thickness and 1 in 6 sections was stained with cresyl violet. One in
6 sections was stained for tyrosine hydroxylase (TH). The staining for TH was carried out on
free-floating sections and was done separately for the cell bodies in the SN and the terminals in
the striatum. For the cell bodies, sections were treated for 5 min with 10% methanol/10%
hydrogen peroxide in distilled water, to remove endogenous peroxidase. Sections were then
washed in Tris-buffered saline, pH7.4 (TBS) and then pre-incubated in 3% normal goat serum
(NGS; Dako, UK) for one hour in TBS containing 0.2% Triton-X100 (TXTBS), to reduce
non-specific staining. The sections were then incubated for 3 days at 4oC in polyclonal tyrosine
hydroxylase antibody (1:3000, Institute Jacques Boy, Rheims, France) in 1% NGS in TXTBS.
Sections were then washed in TBS and incubated in biotinylated anti-rabbit immunoglobulin
(Dako, UK; 1:200 in 1% normal goat serum in TBS). Sections were then washed in TBS and
incubated for 2 hours in a streptavidin-biotin-peroxidase kit (Dako, UK; in 1% NGS in TBS).
After washes in TBS and Tris buffer (0.05M Tris/HCL, pH 7.4), the sections were treated
with 3,3'-diamino benzidine (1% in Tris buffer). The sections were washed in Tris buffer,
mounted on 1% gelatin-coated microscope slides and left to dry over night. After rehydration
and dehydration through graded alcohols, the slides were cleared in xylene and coverslipped
using DPX mountant.
TH staining of the striatal terminals was carried out as above with a few modifications. To
remove endogenous peroxidases, the sections were incubated for 10 minutes in 10%
methanol/3% hydrogen peroxide. Potassium phosphate buffered saline (KPBS) was used
instead of TBS for all rinses and solutions. The sections were not preincubated in NGS, but
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for all other steps NGS was used at 2% rather than 1%. The sections were incubated
overnight at room temperature in a different polyclonal tyrosine hydroxylase antibody (1:2000,
Pel-Freeze, Rogers, AR, USA; in 2% NGS in 0.25% triton in KPBS). The sections were
incubated in the streptavidin-biotin-peroxidase kit for one hour rather than two.
Quantification of TH-immunoreactive cells (TH-IR) in the SNpc
Prior to analysis, the borders of the SNpc were defined. In the anterior sections, the pars
compacta cells were the only TH cells visible. In the central and caudal sections the border
between the ventral tegmental cell group and the pars compacta region was just lateral to the
roots of the third nerve. At the most caudal level, the pars compacta was defined as the dense
TH cell group ventral to the medial lemniscus and the retrorubral area. The TH positive cells
in the pars retriculata (and therefore dorsal to the cerebral peduncle) were included in the cell
counts. This definition led typically to 7-8 sections per monkey being measured.
The number of TH-IR cells was quantified using the unbiased stereological method of the
optical fractionator (58), as outlined in Kirik et al (29). Sampling was done using an Olympus
CAST-Grid system (Olympus Danmark A/S, Denmark). After the region of interest was
delineated for each slide, the first sampling counting frame was randomly placed over the
region of interest. The counting frame was then systematically moved through the counting
area until the whole area was sampled. The size of the counting frame was predetermined and
a frequency was chosen so that between 100 and 200 cells would be counted per SNpc. The
total number of cells was estimated based on the optical fractionator formula (58).
Quantification of striatal TH-IR fibre density
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Optical densitometry readings were made of the TH-IR fibres in the striatum using a NIH 1.60
Image program on a Macintosh 7100/66 computer. The computer was connected to an MT1-
72 CCD video camera and a constant illumination table. Readings were made from nine
rostro-caudal levels of the striatum one millimetre apart starting from AP13.5 and moving
caudally, according to the atlas of Stephan et al (53). Readings from the corpus callosum were
used to correct for non-specific background density levels.
Behavioural Tests
The person undertaking all the behavioural assessment (AE) was unaware of whether the
monkeys had had 6-OHDA or saline injections.
Disability rating scale: This rating scale was used to quantify a variety of behavioural signs
which could be regarded as ‘parkinsonian’. Although the current experiment involved
monkeys with unilateral lesions, we have previously found that non-lateralised measures can
be sensitive to unilateral lesions (LEA, personal observations). The degree to which monkeys
presented parkinsonian features in both spontaneous and induced behaviour was recorded. The
readings were made in the home room when other non-experimental monkeys in the room
were active (e.g. mid-morning or mid-afternoon, but not immediately after feeding). For
spontaneous behaviours, the observer stood approximately 2m in front of the cage, and scored
the behaviour in 3 separate one minute intervals. The following were assessed: 1) akinesia, 2)
climbing, 3) abnormal posture and 4) tremor. The monkeys were given a score from 0 to 3 for
each of these behaviours for each minute, with 3 representing the most impairment and 0 being
normal behaviour. For induced behaviour, the observer tempted each monkey 3 times with a
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small piece of marshmallow (~3mm3) and on each occasion the monkey was given a score of 0
to 3 on: 1) clumsiness, 2) bradykinesia, and 3) poor balance. For each monkey the overall
score consisted of the total scores for spontaneous and induced behaviours to give a score of
63 for maximum impairment. Monkeys were assessed before lesion and at one, 2, 6, and 10
weeks after the lesion.
Head position bias: Monkeys with unilateral dopaminergic lesions tend not to initiate
movement into their contralesional side and as a result show a postural bias towards the
ipsilesional side. The head bias score was a quantification of the time the monkeys spent with
the head turned toward the lesioned side. The observer rated the head position with respect to
the rest of the body (i.e. left, right, or straight ahead) every second for 3 minutes. This was
repeated on 4, usually consecutive, days. For each monkey the final score consisted of the
average number of seconds per day spent with the head turned ipsilesionally minus the number
of seconds spent with the head turned contralesionally. Monkeys were assessed before lesion
and at one, 2, 6, and 10 weeks after the lesion.
Rotation: The monkeys were assessed for both spontaneous and drug-induced rotation. For
spontaneous rotation each monkey was placed in a Plexiglass box (~ 20cm wide x 15cm deep
x 15cm high) in a test room and videotaped for 30min, during which time the experimenter left
the room. For amphetamine-induced rotation each monkey was injected intramuscularly with
amphetamine (Sigma, St Louis, MO, USA; 0.5mg/kg dissolved in saline) 30min before being
videotaped for 30min. For apomorphine-induced rotation each monkey was injected
intramuscularly with apomorphine (Sigma, St Louis, MO, USA; 0.05mg/kg dissolved in 0.1%
ascorbate in saline) immediately before being videotaped for 60min. Monkeys were assessed
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before lesion, at one week after the lesion for spontaneous rotation, and at 2, 6, and 10 weeks
after the lesion for spontaneous and drug-induced rotation.
Staircase task: The staircase task is analogous to the ‘staircase test’ used for rats (38, 39) to
assess skilled forelimb reaching. For this task, monkeys were tested individually in their home
cages after their cage mate had been removed for the duration of the test session. The test
apparatus was fixed to the front of the cage and the monkey was required to reach through a
vertical slot on the left or right side of a Plexiglass apparatus in order to retrieve syrup-soaked
bread pieces (~5mm3) arranged on a series of five steps ascending towards the midline. An
angled inner wall ensured that the monkey had to use its left hand to retrieve bread from the
left side and the right hand to retrieve bread from the right side. Each monkey was presented
with 18 trials over 2-3 days. There were 6 trials in which both sets of steps were baited, 6
trials in which only the steps on the left were baited, and 6 trials in which only the steps on the
right were baited. The trials were presented in a fixed balanced order and the monkey was
allowed 5 min to complete each trial. The total number of pieces removed and the time taken
to remove all bread pieces (‘time-to-clear’) were recorded. Monkeys were trained prelesion
until they were familiar with the apparatus and could readily retrieve the bread pieces from all
the steps. Monkeys were assessed before lesion and at 2, 6, and 10 weeks after the lesion.
Object retrieval task (ORT): This was an adaptation of the ORT first used by Diamond and
colleagues (13, 14) to measure the motor planning involved in making detour reaches around a
transparent barrier to obtain a reward. A correct response required the monkey to be able to
control its arm movements, to choose which arm to use on different trials, and to reach around
rather than towards a transparent barrier. The latter requires the inhibition of a direct reach
towards a visible reward. Training and testing was started approximately 3.5 months
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postlesion. The monkey was placed in a holding chamber which was opaque except for the
transparent front face which had a horizontal slot through which the monkey could reach. This
face could be covered by an opaque screen between trials. On each trial the monkey was
required to reach through the slot to retrieve a piece of marshmallow from a transparent test
box (5cm x 5cm x 5cm). The test box had only one open side which faced towards the
monkey’s left or right side, in a pseudorandom order across trials. Each monkey was given 22
trials each day and was allowed up to two minutes to retrieve the marshmallow on each trial.
Testing continued until the monkey had retrieved at least 20 marshmallow pieces in the 22
trials on each of three consecutive days or for 14 days. Data were analysed for the last three
days of testing, i.e. 66 trials. Trials were scored ‘perfect’ if the reward was taken in one
smooth movement using the appropriate arm (left on the left side, right on the right side). All
other trials were scored ‘imperfect’. For imperfect trials, the number of ‘motor errors’ and
‘barrier reaches’ were counted. A motor error occurred when the appropriate arm was
directed towards the opening but the food piece was not retrieved because it was dropped or
knocked aside. A barrier reach was a reach that encountered the front or the closed side of the
box and was, therefore, unsuccessful in retrieving the reward. Repeated barrier reaches were
frequently made within one trial and were scored as separate reaches. When the opening was
facing the monkey’s contralesional side, two types of barrier reach could be made: Type 1,
when the appropriate contralesional hand encountered the closed front of the box and Type 2,
when the inappropriate ipsilesional hand encountered the closed front or the closed ipsilesional
side of the box. Similarly, when the opening was on the ipsilesional side two further types of
barrier reach could be made: Type 3, when the inappropriate contralesional hand encountered
the closed front or the closed contralesional side of the box and Type 4, when the appropriate
ipsilesional hand encountered the closed front of the box (see Fig. 7).
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Testing after a-methyl-p-tyrosine (AMPT) administration: At approximately 5 months
postlesion, when all the previous behavioural testing had been completed, the monkeys were
assessed after administration of AMPT, a tyrosine hydroxylase inhibitor which reduces
dopamine levels. The monkeys were given doses of 0 (saline injection), 20, 80, 160, or
240mg/kg AMPT (Sigma, St Louis, MO, USA; dissolved in saline, intramuscularly), 3-4h
before being tested on the disability rating scale, head position bias, and the staircase task.
AMPT injections were separated by at least 2 days.
Results
Statistical analysis: Postlesion data were analysed for within- and between-group effects using
a repeated measures ANOVA. Where there were significant interactions, post hoc
comparisons were made using Bonferroni t-tests. Prelesion comparisons between groups were
made using t-tests.
Histology:
Nigral cell counts: 6-OHDA lesioned monkeys had a significant loss of TH-IR cells in the
substantia nigra ipsilateral to the lesion, with an average cell count of only 46% of the cell
count on the intact side (see Table 2 and Fig 1). Repeated measures ANOVA showed a
significant group effect (F[1,10] = 9.06, P<0.05), a significant effect of side (F[1,10] = 66.73,
P<0.001), and a significant group x side interaction (F[1,10] = 131.35, P<0.001). Post hoc
analysis revealed a significant difference in cell count between the injected and uninjected side
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in the 6-OHDA lesioned monkeys (Bonferroni t = 13.880, P<0.001) but no difference in the
sham lesioned monkeys.
TH-density measures of the striatum: Injection of 6-OHDA resulted in a loss of TH-IR Fibres
in the striatum (see Table 3 and Fig 2). The density of TH staining in the injected hemisphere
as a percentage of the density in the uninjected hemisphere was 66% for the caudate nucleus,
72% for the putamen and 67% for the nucleus accumbens. Repeated measures ANOVA of the
average density measures revealed a significant effect of side (F[1,10] = 58.64, P<0.001) and a
significant group x side interaction (F[1,10] = 67.23, P<0.001). Post hoc analysis showed that
there was a significant loss of TH staining in the ipsilesional hemisphere in the 6-OHDA
injected monkeys compared with staining in the contralesional hemisphere (Bonferroni t =
11.21, P<0.001).
Behavioural Assessment
Postoperative recovery: All animals were returned to their home cages and cage mates on the
day following surgery. They all displayed some change in posture and demeanour (see
Disability rating scale and Head position bias) but they were all capable of feeding and self-
care. Despite the changes in skilled hand use on the Staircase task and the Object retrieval
task (see below), animals displayed no gross changes in the integration of contralesional arm
movements in the automatic behaviours of normal locomotion and other daily activities.
Disability rating scale: Before surgery, the disability rating scores of the 2 groups did not
differ significantly (t = 1.853, n.s.). Following surgery, the 6-OHDA lesioned group had higher
disability rating scores than the saline group (F[1,10] = 12.274, P<0.01) but there was no
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group x week interaction (F[1,10] = 3.364, n.s.), see Fig 3A. The disability consisted mainly of
hunched posture, reduced movement and failure to climb. No tremor was observed.
Following AMPT administration, there was a significant difference between groups (F[1,10] =
19.917, P<0.01), a significant dose effect (F[3,30] = 10.254, P<0.001), and a significant group
x dose interaction (F[3,30] = 6.542, P<0.05). Post hoc analysis revealed significant differences
between the 6-OHDA lesioned group and the sham lesioned group at the two highest doses
(160mg/kg, Bonferroni t = 3.627, P<0.05; and 240mg/kg, Bonferroni t = 4.880, P<0.01), see
Fig 3B. AMPT was given approximately 5 months after surgery by which time the 6-OHDA
lesioned monkeys did not show any spontaneous impairment (see effect of saline injection in
Fig 3B). However, AMPT produced a dose-dependent increase in disability rating scores in
the 6-OHDA lesioned monkeys but was without effect on the sham lesioned monkeys.
Head position bias: Before surgery, both groups had similar unbiased scores on the head
position bias test (t = 1.060, n.s.). Following surgery, the 6-OHDA lesioned monkeys spent
more time with their head towards the ipsilesional side compared to sham lesioned monkeys
who showed no head position bias (F[1,10] = 20.191, P<0.01). There was a significant effect
of time (F[3,30] = 16.484, P<0.001) and a time x group interaction (F[3,30] = 9.705,
P<0.001). Post hoc analysis revealed that 6-OHDA lesioned monkeys spent significantly more
time with the head turned ipsilesionally than saline animals at weeks one (Bonferroni t = 3.735,
P<0.05) and two (Bonferroni t = 3.537, P<0.05), but not thereafter, see Fig 4A.
Following AMPT administration there was a significant group difference in head position bias
(F[1,10] = 31.35, P<0.001) and a significant group x dose interaction (F[3,10] = 4.243,
P<0.05). Post hoc analysis revealed that 6-OHDA lesioned monkeys turned their heads
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ipsilesionally at all doses of AMPT in comparison to sham lesioned monkeys (80mg/kg,
Bonferroni t = 3.692, P<0.05; 160mg/kg, Bonferroni t = 3.270, P<0.05; 240mg/kg,
Bonferroni t = 4.198, P<0.01), see Fig 4B.
Rotations: Before surgery, neither group had a rotational bias, either spontaneously or after
amphetamine or apomorphine administration. Following surgery, none of the monkeys rotated
spontaneously. After amphetamine administration, only one 6-OHDA lesioned monkey
showed substantial ipsilesional rotation at 2, 6, and 10 weeks. The lesion in this monkey was
in the mid-range as assessed by TH-IR histology. The other monkeys in the 6-OHDA group,
along with the sham lesioned monkeys, did not rotate substantially after amphetamine
administration (data not shown). Following apomorphine administration, in contrast, 6-OHDA
lesioned monkeys showed substantial contralesional rotation compared with the sham lesioned
monkeys (F[1,10] = 5.691, P<0.05). Hoever, there was a significant week x group interaction
(F[2,20] = 7.505, P<0.01) and the apomorphine-induced rotation was lost by week 10, see Fig
5.
Staircase task: Before surgery, both groups had similar time-to-clear scores and removed the
same number of food pieces from the staircase steps. Following surgery, the 6-OHDA lesioned
monkeys performed more slowly than the sham lesioned monkeys, but they did not show a
specific difficulty with the contralesional arm on this task. ANOVA of the time-to-clear scores
revealed a significant lesion x week interaction (F[2,20] = 3.624, P<0.05) indicating that in
comparison to the sham lesioned monkeys, the 6-OHDA lesioned monkeys had higher time-to-
clear scores as the weeks progressed, see Fig 6A.
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Following AMPT administration, the 6-OHDA lesioned monkeys had higher time-to-clear
scores than the control monkeys (F[1,10] = 5.463, P<0.05), see Fig 6B. There was no
significant group x dose effect (F[3,30] = 2.035, n.s.). However, there was no difference in
performance between the contralesional hand and ipsilesional hand in the 6-OHDA lesioned
monkeys. 6-OHDA lesioned monkeys retrieved fewer food pieces than did sham controls
(F[1,10] = 6.139, P<0.05). There was an interaction between the dose of AMPT and group in
the number of food pieces retrieved (F[3,30] = 8.401, P<0.001) in that the 6-OHDA lesioned
monkeys retrieved fewer food pieces at higher doses of AMPT.
Object retrieval task: There was no difference between the 6-OHDA lesioned monkeys and
the sham lesioned monkeys in the number of trials in criterion that were perfect, i.e. in which
reward was taken in one smooth movement using the appropriate arm (left arm on the left
side, and right arm on the right side). However, amongst the imperfect trials the groups
differed in the quality of the responses they made. 6-OHDA lesioned monkeys made
significantly more barrier reaches than the sham lesioned monkeys when the box was open on
the contralesional side (F[1,10] = 5.998, P<0.05) comprising both Type 1 errors (barrier
reaches with the appropriate contralesional hand, and Type 2 errors (barrier reaches with the
inappropriate, ipsilesional hand, see Fig 7. Observation of the 6-OHDA lesioned monkeys
indicated that Type 2 errors occurred when they failed to initiate responses with the
contralesional hand and, instead, made repeated attempts with the ipsilesional hand to gain
access to the reward through the closed side of the box. In contrast, when the opening was on
the ipsilesional side, the 6-OHDA lesioned monkeys did not make excess barrier reaches with
either hand (see Fig 7). There was no significant difference between the 6-OHDA lesioned
monkeys and the sham lesioned monkeys in the number of motor errors made with either arm.
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Discussion
The purpose of this study was to characterize the behavioural deficits occurring after unilateral
injections of 6-OHDA into the caudate, accumbens and putamen in marmoset monkeys. Such
injections produced a behavioural syndrome that was of limited duration for some measures,
but that was reinstated by the administration of AMPT. 6-OHDA injections reduced the
number of TH-IR cells within the substantia nigra to ~46% and the TH-IR density in the
striatum to ~68% compared to the non-injected side.
Intrastriatal injections of 6-OHDA resulted in a variety of behavioural impairments. The
lesioned monkeys displayed parkinsonian signs after surgery as measured by the disability
rating scale. By 10 weeks postlesion, the rating score for 6-OHDA lesioned monkeys had
recovered to prelesion levels. Treatment with AMPT reinstated a dose dependent deficit on
this measure suggesting that functional compensation involving dopamine systems, such as its
synthesis or storage, were involved in the recovery seen postlesion.
6-OHDA lesioned monkeys spent substantially more time with their head oriented towards
their ipsilesional side, with the highest level being seen at one week postlesion. This
impairment returned to baseline levels by 6 weeks postlesion. Head position bias has been
shown to be a reliable measure of sensorimotor deficits in DA depleted marmosets. Annett and
colleagues (1) reported that the greatest levels of head bias were seen one week after 6-
OHDA lesions of the substantia nigra after which there was a gradual decline in the levels of
bias, although the head bias did not return to prelesion levels in the case of these near
complete dopamine lesions. In the present study the administration of AMPT reinstated head
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bias to levels seen at one week postlesion. This indicates that along with the disability rating
scale, head position bias is a useful measure of behavioural deficit but sensitive to recovery.
The quantification of rotational behaviour occurring after unilateral lesions of the DA system
is a standard tool for assessing dopamine loss within the nigrostriatal system (52). In the
present study, 6-OHDA lesioned monkeys rotated contralesionally after apomorphine
administration at 2 and 6 weeks postlesion but had returned to baseline levels by week 10
postlesion. They did not, however, rotate spontaneously or in response to amphetamine. This
differs from the effects of 6-OHDA lesions of the substantia nigra, nigrostriatal bundle or basal
ganglia in rats or the effects of nigrostriatal bundle lesions in marmosets, where both
amphetamine and apomorphine induced rotations are seen. A possible source for this
discrepancy may lie in the level of locomotor activity resulting from injections of these two
drugs. Unlesioned marmosets show a marked increase in locomotion in response to injections
of apomorphine but not in response to injections of amphetamine over a wide dose range (45).
If the level of locomotor activity contributes to the rate of rotation, particularly at lower lesion
sizes, this may produce differential results. A rotational response to amphetamine may only be
seen in marmosets with the very large unilateral DA depletions achieved by bundle
nigrostriatal lesions.
The staircase task has previously been used in marmoset monkeys to assess skilled
sensorimotor ability (24, 27). 6-OHDA lesioned monkeys in the present study were slower and
somewhat less successful at retrieving rewards in this task especially under AMPT, although
there was no significant effect of side and, therefore, of hand. Unilateral 6-OHDA partial
lesion studies in rats have shown a variable contralesional paw deficit, perhaps dependent on
lesion size (2, 34, 34, 47). Recovery of paw deficits may also occur (46). Ipsilesional hand
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deficits may occur in sensorimotor tasks, particularly with the complete unilateral lesion model
(e.g. (37, 38, 41). Miklyaeva and colleagues (37) reported that ipsilesional deficits in a
reaching task may occur as a consequence of postural abnormalities associated with unilateral
nigrostriatal DA loss.
The object retrieval task was originally designed to measure deficits in human infants and
rhesus monkeys (13). The task assesses the degree to which monkeys are able to make detour
reaches around a transparent barrier, an ability shown to be sensitive to DA loss (55). In order
to succeed monkeys need to refrain from making inappropriate arm movements that are
directed at the barrier. Taylor and colleagues (55, 56) have shown that monkeys treated with
MPTP, that are asymptomatic for gross motor deficits, make more inappropriate responses
directed at the barrier compared to untreated controls. In the present experiment, 6-OHDA
lesioned monkeys made more barrier errors when the open side of the test box was facing their
contralesional side. Specifically, when the box was open on the contralesional side, 6-OHDA
lesioned monkeys had poor motor control of their contralesional hand and made incorrect
reaches towards the front barrier with that hand. However, they made even more barrier
reaches in this position with their ipsilesional hand. This suggests that these monkeys were
reluctant to use the appropriate contralesional hand, but were motivated enough to resort to
using their inappropriate ipsilesional hand, thereby making a substantial number of barrier
reaches with that hand. The increase in use of the ipsilesional hand is probably a natural
consequence of this reluctance to use the contralesional hand rather than an effect of the lesion
on the motor control of the ipsilesional arm. It is noteworthy that at three and a half months
postlesion, at a time when behavioural recovery had taken place on other measures, the ORT
was still able to detect sensorimotor behavioural deficits.
23
The tyrosine hydroxylase inhibitor AMPT reinstated or exacerbated deficits on the disability
rating scale, head position bias and the staircase task. This suggests that compensatory
mechanisms involving dopamine were involved in the recovery seen postlesion. Axonal
sprouting of the remaining dopamine cells, an increase in TH activity and an increase in DA
turnover have been observed to occur in rats after 6-OHDA lesions (18, 61), and may be the
basis of the recovery seen in the present study.
The present study has shown that intrastriatal 6-OHDA lesions of the DA system in marmoset
monkeys result in a variety of behavioural deficits which parallel many of the deficits seen in
rodent studies. A number of these deficits in marmosets are prone to recovery but are
reinstated by the TH inhibitor AMPT. The development of a functionally more stable
intrastriatal 6-OHDA model may require a greater level of cell loss than that seen in the
present experiment. Nonetheless the intrastriatal 6-OHDA lesion model in monkeys has
potential for assessing the effects of treatments for PD that aim to curtail disease progression,
such as continuous GDNF delivery via viral vectors.
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Legends
Fig 1. Coronal sections at 3 AP levels through the substantia nigra of a marmoset following
unilateral injection of 6-OHDA in the basal ganglia. The injected side is on the left of the
figure. These digital images were prepared by scanning the microscope slides directly. There is
a reduction in TH-IR cells on the left hand side. See Table 2 for quantification of lesion. Bar =
1mm.
Fig 2. Coronal sections of 3 AP levels through whole brain of a marmoset following unilateral
injection of 6-OHDA in the basal ganglia. The injected side is on the left of the figure. These
digital images were prepared by scanning the microscope slides directly. There is a reduction
in TH-IR staining in the caudate, nucleus accumbens and putamen on the left hand side. See
Table 3 for quantification. Bar = 5mm.
Fig 3. Effects of lesion on disability rating. A: Disability rating before and after lesion. B:
Disability rating 5 months after lesion but 3-4 hours after administration of AMPT. Open
columns: saline injected group. Filled columns: 6-OHDA injected group. *P<0.05, **P<0.01.
Fig 4. Effects of lesion on head position bias. A: Head bias before and after lesion expressed as
mean number of ipsilesional minus contralesional head turns. B: Head bias 5 months after
lesion but 3-4 hours after administration of AMPT. Open columns: saline injected group.
Filled columns: 6-OHDA injected group. *P<0.05, **P<0.01.
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Fig 5. Effect of apomorphine administration on rotation before and after lesion expressed as
mean number of ipsilesional minus contralesional complete rotations. Open columns: saline
injected group. Filled columns: 6-OHDA injected group.
Fig 6. Effect of lesion on time to clear all rewards on the staircase task. A: Before and after
lesion. B: 5 months after lesion but 3-4 hours after administration of AMPT. Open columns:
saline injected group. Filled columns: 6-OHDA injected group.
Fig 7. Effect of lesion on the mean number of barrier reaches on the object retrieval task. The
blob in the cartoon indicates lesion side. When the opening of the box was on the
contralesional side, errors could be made with the contralesional arm (Type 1 errors) or the
ipsilesional arm (Type 2 errors). When the opening of the box was on the ipsilesional side,
errors could be made with the contralesional arm (Type 3 errors) or the ipsilesional arm (Type
4 errors). Open columns: saline injected group. Filled columns: 6-OHDA injected group.
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Table 1 Lesion co-ordinates (mm from ear bar zero)
Site Anterior/Posterior Medial/Lateral Dorsal/Ventral
1 9.0 +/- 6.0 10.5
2 8.0 +/- 6.2 10.5
3 7.0 +/- 6.5 10.0
4 12.5 +/- 3.0 12.0
5 11.5 +/- 4.4 10.0
6 10.5 +/- 2.6 12.2
7 13.0 +/- 2.0 9.2
8 12.0 +/- 2.0 9.2
9 11.0 +/- 2.2 9.2
Coordinates based on stereotaxic atlas of Stephan et al. (53)
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Table 2 Cell counts in substantia nigra ( +/- sem)
Uninjected side Injected side % of uninjected side
Saline injected 33016 +/- 2547 36461 +/- 1760 110
6-OHDA injected 38155 +/- 1293 17607 +/- 1147 46
The coefficient of errors for estimates of total cell counts were <0.1 for each group/side as
calculated by the method of Gundersen and Jenson (22).
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Table 3 Density of tyrosine hydroxylase staining (density units +/- sem)
Uninjected side Injected side % of uninjected side
Saline injected
Caudate 67.19 +/- 1.63 68.87 +/- 1.73 102.5
Putamen 67.79 +/- 2.30 69.36 +/- 2.19 102.3
N. Accumbens 65.17 +/- 3.03 64.24 +/- 2.88 98.6
Mean = 101.1
6-OHDA injected
Caudate 70.20 +/- 5.48 46.23 +/- 7.08 65.9
Putamen 72.73 +/- 5.09 52.23 +/- 5.09 71.8
N. Accumbens 70.06 +/- 4.74 46.98 +/- 5.11 67.1
Mean = 68.3
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